Syndax Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, reported a net loss of $285.4 million in 2025 despite significant revenue growth from its two FDA-approved cancer therapies, Revuforj and Niktimvo.
NASDAQ
Syndax Pharmaceuticals' 2024 10-K filing highlights commercial launches of Revuforj and Niktimvo, along with ongoing clinical development programs and financial results.
NASDAQ
Syndax Pharmaceuticals' 10-K filing details its capital stock, anti-takeover provisions, and progress in developing cancer therapies revumenib and axatilimab.